Introduction
============

Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental pollutants that are generated primarily through incomplete combustion of carbon-containing materials. One of the major sources of environmental PAHs is industrial activities that constantly emit high concentrations of PAHs, such as tar distillation and coke production. Substantial epidemiological evidence suggests that long-term exposure to PAH-rich emissions is associated with a higher lung cancer risk in exposed workers ([@r12]). Before exerting their carcinogenic effects, PAHs are metabolically activated to form stable PAH--DNA adducts and cause DNA oxidation, eventually leading to DNA damage ([@r36]). DNA damage can result in chromosome aberrations and genetic instability, and might eventually trigger cancers. Micronucleus (MN) frequency is extensively used as a biomarker of chromosomal damage, genome instability, and cancer risk ([@r7]; [@r8]). Previous studies have reported that occupational exposure to PAHs is associated with higher MN frequency ([@r18]; [@r25]). However, the underlying mechanisms still need to be clarified.

In experimental systems, PAHs have been shown to alter the expression patterns of genes that are relevant to the carcinogenic effects of PAHs ([@r10]; [@r32]). Effects on microRNA (miRNA) expression have been proposed as a mechanism through which environmental exposures might affect gene expression ([@r15]; [@r30]). miRNAs are a class of small noncoding RNAs that function as gene regulators by base pairing with the 3´-untranslated regions of target mRNAs and leading to translational repression or degradation of target mRNAs ([@r1]). There is growing evidence that exposure to environmental pollutants may significantly disrupt miRNA expression patterns ([@r2]; [@r5]; [@r13]; [@r14]; [@r30]). However, few epidemiological studies have examined potential effects of PAH exposures on miRNA expression profiles. miRNAs play crucial roles in a broad range of physiological and pathological processes, including the processes that may affect genetic damage levels, such as DNA damage response ([@r16]; [@r27]) and oxidative stress ([@r29]). Previously, miRNAs were shown to regulate cellular responses to ultraviolet-induced genetic damage *in vitro* ([@r27]). However, no studies have demonstrated effects of miRNAs on PAH-related chromosome damage specifically.

Circulating miRNAs in plasma have the potential to serve as stable noninvasive biomarkers of physiological and pathological conditions ([@r21]). Thus in the present study, we sought to identify plasma miRNAs that are associated with PAH exposures by genome-wide miRNA sequencing and subsequent validation in healthy male coke oven workers with well-characterized PAH exposures. We further evaluated associations between the PAH-associated miRNAs and MN frequency.

Materials and Methods
=====================

*Airborne PAH monitoring*. We collected airborne samples from different workplaces in the coke plant of a steel mill located in southern China and determined the concentrations of 16 PAHs using high-performance liquid chromatography ([@r17]).

*Study subjects*. In a previous study ([@r17]), we enrolled 1,333 coke oven workers (1,126 males and 207 females) who were employed at the coke plant for at least 1 year and worked at the top, side, and bottom of the coke ovens; adjunct workplaces (such as the blower operation room and recycling workshops); or in offices. The present study population is a subset of the previous study and consists of male workers 20--60 years of age. We excluded *a*) workers with a self-reported history of chronic diseases, including cancers, cardiopulmonary diseases, chronic inflammation, and hypertension; *b*) workers who reported taking any medicines in the preceding 3 months; and *c*) workers who did not provide urine and/or blood samples. Thus, a total of 391 workers participated in all parts of this study. After participants provided informed consent, we administered a questionnaire to collect information on demographic characteristics, smoking and drinking habits, medical history, and occupational experiences. Participants were considered smokers unless they had smoked an average of \< 1 cigarette/day for \< 1 year in their lifetime (nonsmokers), and considered drinkers unless they had drunk alcoholic beverages less than once each week for \< 1 year in their lifetime (nondrinkers). Each worker donated approximately 20 mL morning urine and 5 mL fasting venous blood (\~ 4 mL heparin-anticoagulated and \~ 1 mL EDTA-anticoagulated). This study was approved by the Medical Ethics Committee of the School of Public Health, Tongji Medical College.

*Study design*. Based on ambient concentrations of total PAHs measured in our previous study ([@r17]), we classified 256 participants who worked in offices (mean ± SD, 1.13 ± 0.37 μg/m^3^) or at adjunct workplaces (3.72 ± 2.09 μg/m^3^) as the control group, and 135 workers working at the top of the coke oven (90.30 ± 69.51 μg/m^3^) or at the side and bottom of the coke oven (11.08 ± 7.29 μg/m^3^) as the exposed group. Because each of the urinary monohydroxy-PAHs (OH-PAHs) and plasma benzo\[*a*\]pyrene-*r*-7,*t*-8,*c*-10-tetrahydrotetrol-albumin (BPDE--Alb) adducts were significantly correlated with the sum of OH-PAHs (ΣOH-PAHs) (*p* \< 0.001) and because the sum of correlation coefficients was the highest for ΣOH-PAHs (see Supplemental Material, Table S1), we used ΣOH-PAHs as the representative PAH internal exposure biomarker for sample selection for miRNA sequencing in the discovery stage. We selected 20 workers with higher ΣOH-PAHs from the exposed group, and 20 matched workers with lower ΣOH-PAHs from the control group. We intentionally frequency-matched the distribution of important general characteristics, including age (± 5 years), smoking status, pack-years of smoking (± 5 pack-years), drinking status, working years (± 2 years), and body mass index (BMI) (± 2), between these two groups to minimize their confounding effects on miRNA expression profiles. We prepared a 5-mL pooled plasma sample for each group that included 250 μL of plasma from each subject. We then subjected two plasma pools to miRNA sequencing and compared miRNA expression profiles between these two groups. To focus on the most likely related miRNAs in the validation stage, we selected miRNAs based on the following criteria: *a*) demonstrated at least a 5-fold lower or higher expression in the exposed group compared with the control group; *b*) expressed at least 50 copies in at least one group; and *c*) were found to be associated with PAH response, DNA damage, or other DNA damage-related mechanisms, such as oxidative stress, based on an extensive literature review. The remaining plasma of 14 subjects in the discovery stage (5 in the control group and 9 in the exposed group) was enough for quantitative reverse-transcription polymerase chain reaction (qRT-PCR) validation (≥ 200 μL); thus, these 14 subjects were also included in the validation stage.

For the miRNAs that were significantly associated with at least one PAH exposure biomarker, we further evaluated their associations with MN frequency.

*Urinary creatinine and OH-PAH measurements*. We measured urinary creatinine concentration, according to Jaffe's colorimetric method, on an automated clinical chemistry analyzer. We measured 12 urinary OH-PAHs, 10 noncarcinogenic metabolites (1-hydroxynaphthalene, 2-hydroxynaphthalene, 2-hydroxyfluorene, 9-hydroxyfluorene, 1-hydroxyphenanthrene, 2-hydroxyphenanthrene, 3-hydroxyphenanthrene, 4-hydroxyphenanthrene, 9-hydroxyphenanthrene, and 1-hydroxypyrene) and 2 carcinogenic metabolites (6-hydroxychrysene and 3-hydroxybenzo\[*a*\]pyrene), by gas chromatography-mass spectrometry ([@r17]). Limits of quantification (LOQ) were in the 0.1--1.4 μg/L range; for concentrations below the LOQ, we used 50% of the LOQ (see Supplemental Material, Table S2). The molar concentrations of OH-PAHs were calibrated by urinary creatinine and expressed as micromoles per millimole creatinine.

*Determination of plasma BPDE--Alb adducts*. We measured BPDE--Alb adducts in heparin-anticoagulated plasma using a sandwich enzyme-linked immunosorbent assay ([@r4]). We assayed each sample in duplicate. The average concentration of BPDE--Alb adducts for each sample was calibrated by plasma albumin and expressed as nanograms per milligram albumin. The LOQ was 1 ng/mg albumin; concentrations below the LOQ were replaced with 50% of the LOQ (see Supplemental Material, Table S2).

*Cytokinesis-block micronucleus (CBMN) assay*. Using fresh heparin-anticoagulated whole blood, with two duplicate slides for each subject, we performed a CBMN assay according to the standardized protocol developed by [@r8]. We microscopically examined 1,000 binucleated cells on each slide and identified the number of binucleated cells containing MN according to scoring criteria. The MN frequency of each subject was recorded as the mean number of CBMN cells per 1,000 binucleated cells.

*RNA isolation*. We isolated total RNA from the two EDTA-anticoagulated plasma pools collected in the discovery stage for Solexa sequencing; we also isolated total RNA from 200 μL EDTA-anticoagulated plasma from each subject in the validation stage, which was analyzed by qRT-PCR (mirVana PARIS miRNA Isolation Kit; Ambion, Austin, TX). For RNA isolation in the validation stage, we added *Canorhabditis elegans* miRNA cel-miR-39 (synthesized by QIAGEN, Germantown, MD, USA) to the denatured plasma samples to normalize the sample-to-sample variation in the isolation step.

*Solexa sequencing*. Purified small RNA molecules of \< 30 bases were ligated with Solexa adaptors and reverse transcribed into cDNA. We used the purified cDNA for cluster generation and sequencing analysis using the Solexa Sequencer (Illumina, San Diego, CA). We then converted the generated image files into digital-quality data. After removing the adaptors, low-quality reads, and contaminated reads, we compared the clean reads with miRBase 18.0 to identify miRNAs. We calculated the normalized copy number for each miRNA by the equation (*C* × 10^6^)/*N*, where *C* is the number of reads mapped to individual miRNA, and *N* is the total number of aligned reads.

*qRT-PCR assay*. RNAs were reverse transcribed (TaqMan miRNA Reverse Transcription Kit) and then subjected to real-time PCR in duplicate using the TaqMan miRNA Assay Kit and an ABI Prism 7900HT Sequence Detection System (all from Applied Biosystems, Foster City, CA). The miRNA expression levels were normalized against cel-miR-39 and calculated by the 2^--ΔCt^ method, where Ct is the cycle threshold: Δ*C~t~* = *C~t~* ~miRNA~ -- *C~t~* ~cel-miR-39~.

*Target gene prediction and enriched biological function analysis*. We used miRanda (<http://www.microrna.org/microrna/home.do>) and TargetScan (<http://www.targetscan.org/>) to predict the potential target genes of miRNAs, and we conducted Gene Ontology (GO) function enrichment analysis of these target genes using DAVID (Database for Annotation, Visualization and Integrated Discovery) Bioinformatics Resources, 6.7 (<http://david.abcc.ncifcrf.gov>).

*Statistical analyses*. Because 6-hydroxychrysene and 3-hydroxybenzo\[*a*\]pyrene were always below their LOQs, we excluded them from further analyses. The concentrations of the 10 remaining urinary OH-PAHs and plasma BPDE--Alb adducts were natural logarithm (ln) transformed, and the miRNA expression levels measured by qRT-PCR were log~2~ transformed. Thus, we used the transformed urinary OH-PAHs, plasma BPDE--Alb adducts, and miRNA expression levels in the statistical analyses. We evaluated the differences of general characteristics between different groups (control vs. exposed groups in the discovery stage, and discovery vs. validation) by Student's *t*-test (for continuous variables) and chi-square test (for categorical variables). We analyzed between-group differences in urinary OH-PAHs and plasma BPDE--Alb adducts by multivariate covariance analysis, and MN frequency by Poisson regression analysis, with adjustment for several primary confounding factors, including age (continuous), smoking status (yes/no), pack-years of smoking (continuous), drinking status (yes/no), all working years (continuous), BMI (continuous), and/or workplace (control/exposed group), when appropriate.

In the discovery stage, we performed Hierarchical clustering for the miRNAs that showed differential expression in two groups using the PermutMatrix clustering tool ([@r3]). In the validation stage, we used multivariate linear regression models to evaluate associations between miRNA expression levels (as the dependent variable) and creatinine-corrected urinary OH-PAHs or plasma BPDE--Alb adducts, with adjustment for the above confounding variables. To compare the magnitude of these associations, we reported standardized coefficients (β~std~) that represent the estimated difference in log~2~-transformed miRNA expression (in SD units) associated with a 1-SD increase in the ln-transformed PAH exposure levels.

In previous work (Zhang X, Guan L, Huang K, Zhang WZ, Hu D, He YF, Li J, Lin DF, Guo YJ, Wu TC, unpublished data) and in the present study (see Supplemental Material, Table S3), OH-PAHs and BPDE--Alb adducts were significantly associated with MN frequency. Thus, to minimize the confounding effects of PAH exposure, we also adjusted for ln-transformed ΣOH-PAHs (continuous) and BPDE--Alb adducts (continuous) in Poisson regression models to evaluate the associations of log~2~-transformed miRNA expression levels (in SD units) with unstandardized MN frequency (as the dependent variable). The frequency ratio (FR) was calculated based on the equation *e*^βstd^ and represented the proportional changes of MN frequency due to 1-SD increase in log~2~-transformed miRNA expression. We evaluated the differences in the associations between miRNA and MN frequency in workers with different drinking status, smoking status, or age group by modeling interaction terms of (miRNA \* stratum variables) in Poisson regression models. We carried out all data analyses using SPSS (version 12.0). Two-sided *p* \< 0.05 was considered statistically significant.

Results
=======

*Subject characteristics*. As shown in [Table 1](#t1){ref-type="table"}, in the discovery stage, the distribution of age, smoking status, pack-years of smoking, drinking status, number of working years, and BMI were matched between the control group and exposed group (all *p* \> 0.05), whereas the PAH exposure levels and MN frequencies were all significantly different between these two groups (all *p* ≤ 0.005). The distribution of general characteristics, most of the PAH internal exposure biomarkers (except for 1-hydroxynaphthalene, 3-hydroxyphenanthrene, and BPDE--Alb adducts), and MN frequency for the 40 subjects in the discovery stage were not significantly different from the other 351 workers in the validation stage (all *p* \> 0.05).

###### 

General characteristics, PAH exposure concentration, and MN frequency in the discovery and validation populations.

  Variable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Discovery stage     *p-*Value              Validation population (*n* = 365)^*a*^   *p-*Value^*b*^      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- ---------------------- ---------------------------------------- ------------------- ------------
  General characteristic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Age (years)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          39.85 ± 5.97        41.74 ± 7.82           0.394^*c*^                               42.15 ± 8.12        0.314^*c*^
  Smoking status \[yes/no (% yes)\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    15/5 (75.0)         14/6 (70.0)            0.723^*c*^                               252/113 (69.0)      0.619^*c*^
  Pack-years of smoking                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                10.69 ± 11.18       15.07 ± 15.13          0.305^*c*^                               12.88 ± 15.14       0.965^*c*^
  Drinking status \[yes/no (% yes)\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   6/14 (30.0)         9/11 (45.0)            0.327^*c*^                               160/205 (43.8)      0.441^*c*^
  No. of working years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 18.55 ± 6.20        22.04 ± 8.59           0.149^*c*^                               20.94 ± 9.59        0.720^*c*^
  BMI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  24.18 ± 3.30        23.85 ± 3.43           0.754^*c*^                               24.10 ± 3.19        0.832^*c*^
  PAH internal exposure biomarker^*d*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  1-Hydroxynaphthalene (× 10^--2^)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     0.54 (0.44, 0.65)   4.28 (3.53, 7.32)      \< 0.001^*e*^                            1.11 (0.67, 1.82)   0.045^*e*^
  2-Hydroxynaphthalene (× 10^--2^)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     0.64 (0.33, 0.86)   3.68 (2.54, 6.15)      \< 0.001^*e*^                            1.13 (0.62, 1.68)   0.148^*e*^
  2-Hydroxyfluorene (× 10^--3^)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        2.19 (1.79, 3.65)   13.22 (8.22, 27.19)    \< 0.001^*e*^                            4.73 (2.96, 7.41)   0.450^*e*^
  9-Hydroxyfluorene (× 10^--3^)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        0.69 (0.06, 1.78)   7.15 (3.39, 19.84)     \< 0.001^*e*^                            2.72 (1.02, 5.87)   0.730^*e*^
  1-Hydroxyphenanthrene (× 10^--3^)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    0.79 (0.50, 1.51)   16.81 (9.93, 25.59)    \< 0.001^*e*^                            3.96 (1.93, 7.47)   0.557^*e*^
  2-Hydroxyphenanthrene (× 10^--3^)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    0.71 (0.52, 1.03)   6.30 (3.78, 12.11)     \< 0.001^*e*^                            1.46 (0.85, 2.77)   0.127^*e*^
  3-Hydroxyphenanthrene (× 10^--3^)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1.19 (0.68, 1.62)   7.46 (3.45, 16.03)     \< 0.001^*e*^                            1.81 (1.01, 3.21)   0.031^*e*^
  4-Hydroxyphenanthrene (× 10^--3^)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1.69 (0.32, 2.46)   4.00 (2.84, 12.98)     0.005^*e*^                               1.73 (0.68, 3.31)   0.408^*e*^
  9-Hydroxyphenanthrene (× 10^--3^)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1.21 (0.73, 1.78)   12.18 (10.22, 18.93)   \< 0.001^*e*^                            3.51 (2.00, 6.66)   0.963^*e*^
  1-Hydroxypyrene (× 10^--2^)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          0.68 (0.52, 0.90)   7.50 (4.95, 11.15)     \< 0.001^*e*^                            1.31 (0.82, 2.39)   0.052^*e*^
  ΣOH-PAHs (× 10^--2^)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 3.16 (2.59, 3.41)   21.09 (17.37, 37.44)   \< 0.001^*e*^                            6.12 (4.27, 9.43)   0.134^*e*^
  BPDE--Alb                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            3.94 (3.43, 4.51)   6.33 (4.41, 10.01)     0.002^*e*^                               4.20 (3.45, 5.17)   0.005^*e*^
  Chromosome damage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  MN frequency (per 1,000 cells)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       2 (1,3)             4 (3,6)                \< 0.001^*e*^                            3 (2, 5)            0.092^*e*^
  Values shown are mean ± SD, median (25th percentile, 75th percentile), or *n* (%). ^***a***^For all variables, ^*n*^ = 365. ^***b***^Comparisons between 40 workers in the discovery stage and the other 351 workers in the validation stage. ^***c***^*p*-Value determined by Student's *t*-test for continuous variables and by chi-square test for categorical variables. ^***d***^Units for OH-PAHs are μmol/mmol creatine, and units for BPDE--Alb adducts are ng/mg albumin. ^***e***^Multivariate covariance analysis was performed for PAH internal exposure biomarkers, and Poisson regression analysis was performed for MN frequency, with adjustment for age, smoking status, pack-years of smoking, drinking status, number of working years, BMI, and/or workplace when appropriate.                                                                                                           

*miRNA expression profiles and miRNA selection for validation*. In the discovery stage, we detected a total of 217 and 153 miRNAs in the plasma pools of the control group and the exposed group, respectively ([Figure 1A](#f1){ref-type="fig"}). The miRNA expression levels in these two groups were strongly correlated (*R*^2^ = 0.844) ([Figure 1B](#f1){ref-type="fig"}). Notably, compared with the expression levels in the control group, 68 miRNAs demonstrated at least a 5-fold lower expression in the exposed group \[all fold changes (FC) ≤ --5\] ([Figure 2](#f2){ref-type="fig"}), whereas no miRNA showed at least a 5-fold higher expression in the exposed group. Based on the miRNA selection criteria (see "Materials and Methods"), we selected 7 highly differentially expressed miRNAs from these 68 down-regulated miRNAs. Moreover, there were 3 miRNAs (miR-542-3p, miR-541-3p, and miR-150-5p) that showed at least a 2-fold higher expression in the exposed group than in the control group (+2 ≤ all FC \< +5) ([Figure 2](#f2){ref-type="fig"}). We also selected 1 miRNA (miR-150-5p) from these 3 mildly up-regulated miRNAs that expressed ≥ 50 copies in at least one group. The expression levels and the related functions of 8 selected miRNAs are shown in [Table 2](#t2){ref-type="table"}.

![miRNA expression profiles in the discovery stage. (*A*) Distribution of miRNAs in the control group and the exposed group. (*B*) Scatter plots showing the relationship of the log~2~-transformed expression levels of miRNAs between the two groups.](ehp.1307080.g001){#f1}

![Heat map of the log~2~-transformed expression levels of 68 miRNAs significantly down-regulated (FC ≤ --5) in the exposed group compared with the controls, and 3 miRNAs (miR-542-3p, miR-541-3p, and miR-150-5p) mildly up‑regulated (+2 ≤ FC \< +5) in the exposed group compared with the controls. Gray indicates no detection.](ehp.1307080.g002){#f2}

###### 

Expression levels and related functions of the eight selected miRNAs.

  miRNA                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Discovery stage^*a*^   FC^*b*^   Validation stage^*c*^   Related functions      References                                                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- --------- ----------------------- ---------------------- ------------------------------------------------------------------------- -----------------------------------------------------------
  miR-24-3p                                                                                                                                                                                                                                                                                                                                                                                                                                                                     1,109                  10        --110.9                 0.221 (0.024, 1.193)   DNA damage response; ARNT regulation                                      Lal et al. 2009; Oda et al. 2012; Wang and Taniguchi 2013
  miR-27a-3p                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1,106                  10        --110.6                 0.247 (0.054, 0.924)   ROS-mediated repression; TFIIH regulation                                 Pathi et al. 2011; Portal 2011
  miR-142-5p                                                                                                                                                                                                                                                                                                                                                                                                                                                                    5,901                  470       --12.56                 0.012 (0.003, 0.048)   Benzo\[*a*\]pyrene response                                               Halappanavar et al. 2011
  miR-16-5p                                                                                                                                                                                                                                                                                                                                                                                                                                                                     24,442                 2080      --11.75                 0.622 (0.240, 1.659)   Regulation of DNA damage signaling in response to PAHs                    Niziolek-Kierecka et al. 2012
  miR-451a                                                                                                                                                                                                                                                                                                                                                                                                                                                                      5,493                  475       --11.56                 0.165 (0.077, 0.477)   Regulation of susceptibility to oxidative damage                          Yu et al. 2010
  miR-28-5p                                                                                                                                                                                                                                                                                                                                                                                                                                                                     131                    18        --7.28                  0.006 (0.001, 0.025)   Associated with frequent chromosomal alteration; antioxidant response     Wilting et al. 2013; Yang et al. 2011
  let-7b-5p                                                                                                                                                                                                                                                                                                                                                                                                                                                                     532                    83        --6.41                  0.102 (0.028, 0.307)   Down-regulated by cellular stress; protecting cells from oxidant injury   Hou et al. 2012; Saleh et al. 2011
  miR-150-5p                                                                                                                                                                                                                                                                                                                                                                                                                                                                    88                     252       +2.86                   0.015 (0.008, 0.037)   Benzo\[*a*\]pyrene response                                               Halappanavar et al. 2011
  Abbreviations: ARNT, aryl hydrocarbon receptor nuclear translocator; ROS, reactive oxygen species; TFIIH, transcription factor II H. ^***a***^Mean copy numbers based on Solexa sequencing. ^***b***^Negative values indicate that miRNA expression was lower in the exposed group; positive values indicate that miRNA expression was higher in the exposed group. ^***c***^Values are median (25th percentile, 75th percentile) RT-PCR expression relative to cel-miR-39.                                                                                                                                                             

*Identification of PAH-associated miRNAs.* In the validation stage, we used multivariable linear regression analysis to estimate confounder-adjusted associations of urinary OH-PAH concentrations and plasma BPDE--Alb adducts with the expression of eight selected miRNAs ([Table 3](#t3){ref-type="table"}). Urinary 4-hydroxyphenanthrene concentration was associated with significantly lower expression of miR-24-3p, miR-27a-3p, and miR-142-5p (all *p* \< 0.030), with the strongest association estimated with miR-27a-3p \[β~std~ = --0.141; 95% confidence interval (CI): --0.246, --0.037; *p* = 0.008\]. Plasma BPDE--Alb adducts were associated with lower expression of miR-24-3p and miR-28-5p (all *p* ≤ 0.004), with the strongest association estimated with miR-28-5p (β~std~ = --0.180; 95% CI: --0.290, --0.071; *p* = 0.001). Notably, miR-24-3p was significantly associated with both 4-hydroxyphenanthrene (β~std~ = --0.117; 95% CI: --0.222, --0.013; *p* = 0.028) and BPDE--Alb adducts (β~std~ = --0.166; 95% CI: --0.277, --0.055; *p* = 0.004). miR-150-5p was the only selected miRNA that showed a mildly higher expression in the exposed group (+2 \< FC \< +5) in the discovery stage. In the validation stage, urinary 1-hydroxynaphthalene, 2-hydroxynaphthalene, 2-hydroxyphenanthrene, and ΣOH-PAHs were all associated with higher miR-150-5p expression (all *p* \< 0.030), with the strongest association estimated with 1-hydroxynaphthalene (β~std~ = 0.190; 95% CI: 0.076, 0.303; *p* = 0.001). These five PAH-associated miRNAs were not significantly associated with drinking status, smoking status, or age (all *p* \> 0.05) (see Supplemental Material, Table S4).

###### 

Association of PAH exposure with miRNA expression level (as the dependent variable) \[β~std~ (95% CI)\].

  PAH biomarker^*a*^                                                                                                                                                                                                                                    miR‑24‑3p^*b*^               *p*^*c*^   miR‑27a‑3p^*b*^              *p*^*c*^   miR‑142‑5p^*b*^              *p*^*c*^   miR‑16‑5p^*b*^             *p*^*c*^   miR‑451a^*b*^              *p*^*c*^   miR‑28‑5p^*b*^               *p*^*c*^   let‑7b‑5p^*b*^             *p*^*c*^   miR‑150‑5p^*b*^            *p*^*c*^
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ---------- ---------------------------- ---------- ---------------------------- ---------- -------------------------- ---------- -------------------------- ---------- ---------------------------- ---------- -------------------------- ---------- -------------------------- ----------
  1-Hydroxy­naphthalene                                                                                                                                                                                                                                 --0.007 (--0.125, 0.110)     0.902      --0.024 (--0.138, 0.091)     0.686      0.039 (--0.075, 0.153)       0.503      0.059 (--0.056, 0.174)     0.317      0.074 (--0.040, 0.187)     0.202      0.033 (--0.082, 0.148)       0.576      0.089 (--0.026, 0.204)     0.130      0.190 (0.076, 0.303)       0.001
  2-Hydroxy­naphthalene                                                                                                                                                                                                                                 --0.007 (--0.133, 0.118)     0.908      --0.041 (--0.164, 0.083)     0.517      0.018 (--0.105, 0.141)       0.776      0.078 (--0.047, 0.203)     0.219      0.089 (--0.034, 0.213)     0.156      0.013 (--0.111, 0.137)       0.839      0.080 (--0.046, 0.206)     0.214      0.153 (0.029, 0.277)       0.016
  2-Hydro­xyfluorene                                                                                                                                                                                                                                    --0.058 (--0.163, 0.046)     0.274      --0.037 (--0.142, 0.067)     0.483      --0.074 (--0.178, 0.030)     0.161      --0.031 (--0.136, 0.075)   0.565      --0.033 (--0.137, 0.070)   0.527      0.043 (--0.062, 0.148)       0.424      0.043 (--0.063, 0.149)     0.423      0.013 (--0.093, 0.118)     0.813
  9-Hydro­xyfluorene                                                                                                                                                                                                                                    --0.010 (--0.116, 0.096)     0.857      --0.040 (--0.145, 0.066)     0.461      --0.038 (--0.143, 0.067)     0.482      0.031 (--0.076, 0.138)     0.566      --0.008 (--0.113, 0.097)   0.874      0.037 (--0.069, 0.143)       0.491      0.041 (--0.067, 0.148)     0.459      0.050 (--0.057, 0.156)     0.361
  1-Hydroxy­phenanthrene                                                                                                                                                                                                                                0.037 (--0.075, 0.149)       0.517      --0.046 (--0.157, 0.065)     0.414      0.011 (--0.099, 0.121)       0.846      0.024 (--0.088, 0.136)     0.674      0.022 (--0.088, 0.132)     0.695      0.016 (--0.095, 0.128)       0.771      0.027 (--0.085, 0.139)     0.639      0.074 (--0.038, 0.185)     0.195
  2-Hydroxy­phenanthrene                                                                                                                                                                                                                                0.000 (--0.106, 0.107)       0.996      --0.004 (--0.111, 0.103)     0.945      --0.014 (--0.120, 0.092)     0.799      0.031 (--0.077, 0.139)     0.573      0.007 (--0.099, 0.114)     0.892      0.075 (--0.032, 0.182)       0.171      0.038 (--0.070, 0.146)     0.488      0.121 (0.014, 0.228)       0.026
  3-Hydroxy­phenanthrene                                                                                                                                                                                                                                --0.034 (--0.139, 0.072)     0.529      0.027 (--0.079, 0.134)       0.615      --0.007 (--0.112, 0.099)     0.901      --0.014 (--0.121, 0.093)   0.797      0.016 (--0.089, 0.121)     0.763      0.038 (--0.069, 0.144)       0.488      0.069 (--0.038, 0.176)     0.206      0.046 (--0.061, 0.152)     0.402
  4-Hydroxy­phenanthrene                                                                                                                                                                                                                                --0.117 (--0.222, --0.013)   0.028      --0.141 (--0.246, --0.037)   0.008      --0.121 (--0.225, --0.018)   0.022      --0.065 (--0.171, 0.040)   0.224      --0.035 (--0.139, 0.070)   0.516      --0.063 (--0.168, 0.043)     0.244      --0.029 (--0.134, 0.076)   0.588      --0.053 (--0.158, 0.053)   0.329
  9-Hydroxy­phenanthrene                                                                                                                                                                                                                                --0.063 (--0.168, 0.043)     0.244      --0.030 (--0.136, 0.076)     0.574      --0.019 (--0.125, 0.086)     0.719      0.006 (--0.101, 0.113)     0.917      0.004 (--0.101, 0.108)     0.946      0.004 (--0.103, 0.110)       0.944      0.000 (--0.107, 0.107)     0.998      0.086 (--0.021, 0.193)     0.114
  1-Hydroxypyrene                                                                                                                                                                                                                                       --0.055 (--0.166, 0.056)     0.329      --0.087 (--0.196, 0.023)     0.121      --0.061 (--0.171, 0.048)     0.269      --0.009 (--0.120, 0.102)   0.878      0.017 (--0.092, 0.126)     0.759      --0.017 (--0.128, 0.093)     0.756      --0.027 (--0.138, 0.085)   0.638      0.091 (--0.020, 0.202)     0.107
  ΣOH-PAHs                                                                                                                                                                                                                                              --0.030 (--0.143, 0.082)     0.593      --0.061 (--0.173, 0.050)     0.279      --0.017 (--0.128, 0.094)     0.758      0.035 (--0.078, 0.147)     0.544      0.015 (--0.096, 0.126)     0.793      0.014 (--0.098, 0.126)       0.810      0.048 (--0.066, 0.162)     0.407      0.150 (0.038, 0.261)       0.009
  BPDE--Alb                                                                                                                                                                                                                                             --0.166 (--0.277, --0.055)   0.004      --0.084 (--0.194, 0.026)     0.134      --0.091 (--0.202, 0.019)     0.104      --0.050 (--0.163, 0.064)   0.389      --0.029 (--0.139, 0.081)   0.607      --0.180 (--0.290, --0.071)   0.001      --0.030 (--0.140, 0.080)   0.590      --0.067 (--0.182, 0.047)   0.249
  ^***a***^Values were ln-transformed. ^***b***^Values were log~2~-transformed. ^***c***^Multivariable linear regression analysis with adjustment for age, smoking status, pack-years of smoking, drinking status, working years, workplace, and BMI.                                                                                                                                                                                                                                                                                                                

*PAH-associated miRNAs and MN frequency*. We then investigated whether there were associations between the expression of the five PAH-associated miRNAs and MN frequency. As shown in [Table 4](#t4){ref-type="table"}, the five PAH-associated miRNAs were all associated with higher MN frequency (all *p* \< 0.005), with the strongest association estimated for miR-24-3p (FR = 1.152; 95% CI: 1.086, 1.222; *p* = 2.59 × 10^--6^). We further performed stratification analyses by drinking status, smoking status, and age group. We found that the association of all five of the miRNAs with MN frequency remained significant in drinkers (all *p* \< 0.005), and most associations were significantly stronger in drinkers compared with nondrinkers (all *p*~interaction~ \< 0.015), except for the association between miR-142-5p and MN frequency (*p*~interaction~ = 0.288) ([Table 4](#t4){ref-type="table"}). Although the associations between miRNA expression and MN frequency also remained significant in smokers and workers between 41 and 60 years of age (all *p* \< 0.025), most associations were not significantly different between the corresponding subgroups (all *p*~interaction~ \> 0.05), except for the association of miR-27a-3p with MN frequency between smoking strata (*p*~interaction~ = 0.049) (see Supplemental Material, Table S5).

###### 

Association between miRNA expression and MN frequency (as the dependent variable) \[FR (95% CI)\].

  miRNA^*a*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              All samples (*n* = 365)   *p*^*b*^         Nondrinkers (*n* = 205)   *p*^*b*^   Drinkers (*n* = 160)   *p*^*b*^         *p*~interaction~^*c*^
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- ---------------- ------------------------- ---------- ---------------------- ---------------- -----------------------
  miR-24-3p                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1.152 (1.086, 1.222)      2.59 × 10^--6^   1.035 (0.954, 1.122)      0.407      1.293 (1.182, 1.415)   2.34 × 10^--8^   3.36 × 10^--4^
  miR-27a-3p                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1.093 (1.032, 1.157)      0.002            1.021 (0.944, 1.103)      0.608      1.180 (1.080, 1.290)   2.47 × 10^--4^   0.007
  miR-142-5p                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1.102 (1.041, 1.166)      8.59 × 10^--4^   1.076 (0.996, 1.163)      0.064      1.120 (1.027, 1.221)   0.010            0.288
  miR-28-5p                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1.147 (1.083, 1.216)      3.69 × 10^--6^   1.050 (0.965, 1.144)      0.259      1.236 (1.137, 1.344)   6.68 × 10^--7^   0.013
  miR-150-5p                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1.092 (1.033, 1.155)      0.002            0.997 (0.917, 1.082)      0.936      1.172 (1.084, 1.266)   6.16 × 10^--5^   0.009
  ^***a***^Values were log~2~-transformed. ^***b***^Poisson regression analysis with adjustment for age, smoking status, pack-years of smoking, working years, workplace, BMI, ΣOH-PAHs, BPDE--Alb adducts, and/or drinking status when appropriate. ^***c***^*p*~interaction~ was calculated by entering the interaction term (miRNA\*drinking status) into Poisson regression models, with adjustment for age, smoking status, pack-years of smoking, working years, workplace, BMI, ΣOH-PAHs, and BPDE--Alb adducts.                                                                                                                           

*Enriched biological functions of the target genes*. To explore the potential functions of these five miRNAs, we predicted their target genes. There were 733 putative targets for miR-24-3p, 452 for miR-27a-3p, 66 for miR-142-5p, 432 for miR-28-5p, and 721 for miR-150-5p. GO function enrichment analysis showed that these target genes were mainly involved in 13 enriched biological functions (*p* \< 0.002), including the cellular physiological process, external stimulus response, enzyme activity regulation, and metabolism ([Table 5](#t5){ref-type="table"}).

###### 

Enriched biological functions of the target genes of five identified miRNAs (miR-24-3p, miR-27a-3p, miR-142-5p, miR-28-5p, and miR-150-5p).

  ID           Description                                   *p*-Value
  ------------ --------------------------------------------- ----------------
  GO:0030036   Actin cytoskeleton organization               1.49 × 10^--4^
  GO:0030029   Actin filament-based process                  2.78 × 10^--4^
  GO:0006468   Protein amino acid phosphorylation            3.44 × 10^--4^
  GO:0065009   Regulation of molecular function              5.46 × 10^--4^
  GO:0009605   Response to external stimulus                 5.78 × 10^--4^
  GO:0007242   Intracellular signaling cascade               6.37 × 10^--4^
  GO:0065008   Regulation of biological quality              7.81 × 10^--4^
  GO:0051347   Positive regulation of transferase activity   1.00 × 10^--3^
  GO:0010646   Regulation of cell communication              1.13 × 10^--3^
  GO:0007243   Protein kinase cascade                        1.72 × 10^--3^
  GO:0050790   Regulation of catalytic activity              1.73 × 10^--3^
  GO:0051017   Actin filament bundle formation               1.88 × 10^--3^
  GO:0044267   Cellular protein metabolic process            1.95 × 10^--3^

Discussion
==========

To the best of our knowledge, this is the first study to explore associations between PAH exposure and miRNA expression, and between the same miRNAs and MN frequency, in an occupational population. Our genome-wide miRNA sequencing revealed that miRNA expression profiles were different between two occupational groups with high and low PAH exposure levels, with most miRNAs significantly down-regulated in the high-exposure group compared with the low-exposure controls. In a detailed validation study, we identified five miRNAs that were associated with at least one of the PAH exposures, including four that were negatively associated with urinary noncarcinogenic 4-hydroxyphenanthrene and/or plasma carcinogenic BPDE--Alb adducts (miR-24-3p, miR-27a-3p, miR-142-5p, and miR-28-5p) and one that was positively associated with exposure to three different urinary noncarcinogenic OH-PAHs and with urinary ΣOH-PAHs (miR-150-5p). The same miRNAs also were associated with chromosome damage, as reflected by higher MN frequency, with stronger associations among drinkers than nondrinkers.

Many studies have reported evidence suggesting that environmental stimuli can induce changes in miRNA expression ([@r2]; [@r14]; [@r30]). The present study provides novel information about associations of PAH exposures with plasma miRNA expression in exposed workers. Our genome-wide miRNA sequencing and subsequent validation revealed that most miRNAs were negatively associated with PAH exposure levels, which is similar to the results reported in prior studies regarding the effects of PAH-rich cigarette smoke on miRNA expression patterns ([@r5]). [@r13] reported that cigarette smoke mainly resulted in a remarkable down-regulation of miRNA expression in rat lung. [@r30] observed 28 miRNAs that were differentially expressed in the bronchial airway epithelium in smokers, with most being down-regulated. Moreover, miRNA expression is generally down-regulated in different types of cancer, including lung cancer ([@r20]).

In the present study, miR-24-3p, miR-27a-3p, miR-142-5p, and miR-28-5p were all negatively associated with urinary 4-hydroxyphenanthrene concentrations and/or plasma BPDE--Alb adducts, and positively associated with MN frequency. These miRNAs have been reported to regulate genes that could protect against adverse effects of PAH exposures. miR-24-3p has been reported to negatively regulate *H2AX*, which is crucial in double-stranded break repair; thus, reduced expression of this gene might increase cellular sensitivity to DNA-damaging agents and genomic instability ([@r16]; [@r33]). In addition, miR-24-3p has also been reported to negatively regulate *ARNT* (aryl hydrocarbon receptor nuclear translocator), the protein product of which forms a heterodimer with the aryl hydrocarbon receptor that mediates PAH responses, and to down-regulate the metabolism gene *CYP1A1* (cytochrome P450 1A1) ([@r23]). miR-27a-3p has been proposed to operate with miR-24-3p in a cooperative cluster; it can be down-regulated by reactive oxygen species ([@r24]), and it is a key regulator of *TFIIH*, which displays activities involved in DNA repair processes ([@r26]). miR-27a-3p down-regulation may elevate TFIIH and DNA repair capacity and thus decrease chromosome damage. miR-142-5p is repressed in lung cancer ([@r19]) and down-regulated after exposure to benzo\[*a*\]pyrene ([@r9]). miR-142-5p down-regulation in healthy CD4^+^ T cells can lead to up-regulation of *SAP* (SLAM-associated protein) expression and increase T-cell function and IgG production ([@r6]); thus, it may protect individuals against the deleterious effects of PAHs. miR-28-5p is linked to frequent chromosomal alterations ([@r34]); it negatively regulates *Nrf2* (NF-E2-related factor 2), the protein product of which is an important transcription factor that regulates the expression of detoxifying enzymes ([@r37]). miR-28-5p down-regulation may elevate the expression of *Nrf2* and detoxifying enzymes, and may protect cells from carcinogen-induced DNA damage.

In addition, we found that miR-150-5p expression, which was increased in association with several biomarkers of internal noncarcinogenic PAH exposure, was associated with higher MN frequency. However, [@r9] found that miR-150-5p was down-regulated in the lung of rats exposed to benzo\[*a*\]pyrene. miR-150-5p is a key regulator of *c-Myb*, which is important for immune cell differentiation and activation, and miR-150 deficiency can lead to enhanced immune response ([@r35]). Thus, miR-150-5p up-regulation may decrease immune response to PAH exposure and make individuals more vulnerable to the deleterious effects of PAHs.

The stratification analyses in our study showed that the associations between miRNAs and MN frequency were more prominent in drinkers. These results provided some clues that can be used for more detailed risk assessment.

Our study has several strengths. First, to identify PAH-associated miRNAs, we screened and compared hundreds of miRNAs in pooled plasma samples from high- and low-exposure groups, and then we validated several miRNAs to reduce the false-positive probability. Second, we systematically evaluated the associations of miRNAs with noncarcinogenic and carcinogenic PAH internal exposure biomarkers. For our study, we recruited workers who had been regularly exposed to PAH-rich emissions for at least 1 year, with their major PAH exposure sources and concentrations showing little fluctuation. Thus, it was reasonable to use OH-PAHs and BPDE--Alb adducts as biomarkers of chronic PAH exposure in this population ([@r31]). Moreover, BPDE--Alb adducts cannot be repaired and have a mean residence time of 28 days, which is sufficiently long to dampen the day-to-day variability in exposure levels ([@r4]). Besides, our study subjects had been working in the same factory, minimizing the confounding effects of other PAH exposure sources from the day-to-day environment, socieconomic factors, and other characteristics.

However, because our study is a cross-sectional study in which we measured biomarkers of PAH exposures, miRNA expression levels, and MN frequency at the same time point, it is not possible to determine whether differences in miRNA expression preceded or followed PAH exposures or chromosome damage. Moreover, we validated only a subset of the miRNAs found in the discovery stage, and other miRNAs should be further validated.

Conclusions
===========

We identified five potentially PAH-associated miRNAs in plasma, and the same miRNAs were associated with a marker of chromosome damage in coke oven workers, suggesting that miRNAs might be a novel mechanism mediating the effects of PAH exposure on chromosome damage. Further studies are warranted to verify our findings and determine the underlying mechanisms.

Supplemental Material
=====================
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Click here for additional data file.
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